Imugene Ltd has released a press release.
CF33 Oncolytic Virus Clinical Trial Program Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO
- Investor Presentation - Proposed Acquisition
- New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI
- Appendix 4C - Quarterly and Business Update
- IMU presents new mimotope PD-1 vaccine data at AACR
Later from Imugene
- US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy
- Imugene Receives $4.13 million R&D Tax Incentive
- Imugene Share Placement to raise $24.6 million
- Imugene HER-Vaxx Immunotherapy Patent Granted in US
- Imugene PD1-Vaxx Immunotherapy Update
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene